O herpesvírus 6 Humano (HHV-6) pode causar vários síndromes clínicos incluindo infeções graves em pacientes imunocomprometidos, particularmente em recetores de transplante de células estaminais hematopoiéticas alogénicas (HSCT). A reativação de HHV-6 foi associada a numerosas complicações pós-transplante incluindo graft-versus-host-disease, encephalitis, interstitial pneumonitis, delayed engraftment, fever, and skin rash, responsible for morbidity and mortality. HHV-6 DNA detection and quantification is useful for diagnosing and monitoring infections.
HHV6 R-GENE® offers rapid and specific detection even prior to clinical symptoms, making it an ideal solution. This helps improve options for management, measure the effectiveness of treatment, and monitor for relapse.
The HHV6 R-GENE® kit is a ready-to-use molecular detection and quantification kit. It measures the viral load of HHV6 using real-time PCR after viral DNA extraction. The 5’ nuclease hydrolysis probe technique enables amplification and simultaneous detection of a specific region of the HHV6 genome.
Using the HHV6 R-GENE® kit is easy. Just add the extracted DNA sample to the ready-to-use PCR master mix and start the reaction on the appropriate Real-Time PCR thermocycler, following the optimized cycling program described in the “Instructions For Use”.
HHV6 R-GENE® (69-006B) - Real Time Detection and Quantification kit | |
---|---|
Principle of the test | Genomic detection and quantification of HHV6 |
Ordering information | Reference: 69-006B Designation: HHV6 R-GENE® - Real Time Detection and Quantification kit |
Technology | Real-Time PCR / 5' nuclease technology |
Gene target | U57 gene |
Specimen | - Whole blood - Plasma - CSF - BAL |
Detection limit | LoD 95% : 200 copies/mL (2.3 log copies/mL) |
Dynamic Range of Quantification | 500 to 9.0E+07 copies/mL (2.7 to 8.0 log copies/mL) |
Controls included | Extraction / Inhibition Control, Negative Control, Positive Control (QS3), 4 Quantification Standards, Sensitivity Control |
Results within | 90 minutes (extraction step not included) |
Reporting unit | Copies/mL (possibility to convert into IU/mL with WHO International Standard) |
Number of tests | 90 tests |
Storage conditions | -15°C/-31°C |
Validated extraction platform | - EMAG® - NUCLISENS® easyMAG® - MagNA Pure 96 - QIAsymphony SP |
Validated Amplification platform | - ABI 7500 Fast - ABI 7500 Fast Dx - LightCycler 480 (System II) - Rotor-Gene Q - CFX96 |
Status | For in vitro diagnostic use, CE-IVD marking |
What is HHV-6? Human herpesvirus 6 (HHV-6) is a DNA virus, member of the Herpesviridae family, that includes two species: HHV-6A and HHV-6B. This is an ubiquitous virus with a seroprevalence reaching more than 90% in adult population. Primary infection most often occurs before 2 years old, causing roseola infantum. After primoinfection, HHV-6 remains latent in various cells including monocytes, macrophages, endothelial cells, bone marrow progenitors and central nervous system cells. As a noticeable difference with other human herpesviruses, genomic HHV-6 DNA can be integrated into the cell chromosomes (ciHHV-6) in about 1% of the general population. Who is most at risk? During specific pathological states (e.g. immunocompromised patients), HHV-6 can be reactivated and can impact several organs. In transplant patients, HHV-6 reactivation may result in a wide clinical spectrum: bone marrow suppression, graft rejection, pneumonitis, encephalitis, hepatitis, fever, skin rash... Among these patients, hematopoietic stem cell transplant recipients are particularly at risk of developing an HHV-6 reactivation (about 50% within the first 4 weeks after cell transfer). Severe complications linked to this active infection include delayed engraftment, graft versus host disease, and HHV-6 encephalitis. What are the benefits of HHV-6 testing? HHV-6 DNA detection and quantification with real time PCR assays is useful for diagnosing and monitoring HHV-6 infections. It offers rapid and specific detection and quantification, even prior to clinical symptoms, to help improve options for management, measure the effectiveness of treatment, and monitor for relapse. |